Stomach (Gastric) Cancer: Our Clinical Trials

Clinical trials are research studies that evaluate the safety and effectiveness of new treatment approaches for a disease. If you are being treated for stomach cancer, you may be offered the opportunity to take part in a clinical trial at some point during your treatment.

In some cases, a study may give you access to new therapies that are not yet readily available. Clinical trials may also be used to compare diagnostic tests, prevention strategies, or other aspects of your care.

If you are asked to participate in a clinical trial, your doctor or nurse will explain exactly what is involved and any possible benefits or drawbacks posed by the trial. They will explain to you that that unexpected side effects may occur if you enroll in a clinical trial. You will need to sign an informed consent agreement in order to participate in the trial. Before agreeing to participate, make sure you know what the costs will be and how much your insurance will cover.

You are not required to participate in clinical trials. If you decline, this will not jeopardize your relationship with your physician. You may leave a trial for any reason and at any time, even after signing the agreement.

Showing 11 trials
Title Investigator
A Phase I Study of Debio1347 in Patients with Advanced Cancers Containing FGFR Alterations
[Protocol 13-131]
Voss, Martin, MD
A Phase I Study of TAS-102 plus CPT-11 (Irinotecan) in Patients with Advanced Digestive Cancers
[Protocol 13-105]
Saltz, Leonard, MD
A Phase II Study of Afatinib (BIBW 2992) in Patients with Advanced HER2-Positive Esophagogastric Cancer Refractory to Trastuzumab
[Protocol 11-166]
Janjigian, Yelena, MD
A Phase II Study of FOLFOX plus Regorafenib in Patients with Inoperable or Metastatic Esophageal and/or Stomach Cancer
[Protocol 13-080]
Janjigian, Yelena, MD
A Phase II Study of Ipilimumab versus Standard Chemotherapy after Initial Therapy in Patients with Inoperable or Advanced Gastric or Gastroesophageal Cancer
[Protocol 12-277]
Ku, Geoffrey, MD
A Phase II Study of Neratinib in Patients with Solid Tumors Containing Mutated HER2
[Protocol 13-140]
Solit, David, MD
A Phase II Study of SNX-5422 in Patients with Select Advanced HER2 Cancers
[Protocol 13-112]
Voss, Martin, MD
A Phase III Study of Standard Chemotherapy with and without Rilotumumab as Initial Treatment in Patients with Metastatic or Inoperable Gastric/Esophageal Cancer
[Protocol 13-091]
Ilson, David, MD
A Pilot Study to Identify Patient Factors Impacting Adherence to Oral Chemotherapy
[Protocol 11-194]
Ginex, Pamela, RN, EDD
A Randomized Phase II Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) Treatment versus Conventional DCF with Growth Factor Support in Patients with Unresectable or Metastatic Gastric and Gastroesophageal Junction Cancer
[Protocol 06-103]
Janjigian, Yelena, MD
Early Onset and Familial Gastric Cancer Registry
[Protocol 05-118]
Kelsen, David, MD